Valeant Pharmaceuticals stock ( VRX ) continued its slide, as news of an SEC investigation fueled additional selling on Monday. The embattled drug company's stock has been trending lower for several months now. VRX ended the day down 18% on volume of 27 million shares, triple its recent average daily volume. After a huge run up from 2009 to mid-2015, VRX began showing signs of topping and distribution (selling by major holders) in the fall of 2015. The stock is down 35% year-to-date in 2016 and down 67% over the past year ( Finviz stats, click chart below). Let's take a look at the charts and examine the troubled stock's downtrend, and the huge uptrend that preceded it. I'll also offer some ideas on how to avoid major stock declines (or at least limit your losses in such instances ) . Below, the multi-year consolidation pattern that launched VRX 's 2010 -2015 advance. The stock would climb from $2 3 to over $250 in that 5-year period.